TFFP - TFF Pharma's formulated influenza vaccines show encouraging preclinical action

TFF Pharmaceuticals ([[TFFP]] +4.8%) has announce positive preclinical immunogenicity and efficacy data from thin film freezing formulated UGA universal Influenza hemagglutinin ((HA)) recombinant vaccines. The vaccine is under development in collaboration (announced in April this year) with the University of Georgia’s Center for Vaccines and Immunology.The formulated HA vaccines elicited equivalent neutralizing antibodies and protection against influenza virus infection compared to liquid formulations. Currently, the level of neutralizing antibodies and amount of virus in the lung are being analyzed, in addition to long term stability testing of the TFF HA vaccine.TFF Pharmaceuticals’ testing suggests that Thin Film Freezing maintains a potential vaccine’s particle size distribution and immunogenicity, is robust for extended periods at room temperature, withstands unintentional freezing, and can be stored and shipped free of cold-chain handling and provides for needle-free vaccination.

For further details see:

TFF Pharma's formulated influenza vaccines show encouraging preclinical action